Create an Account
  1. Home
  2. Specialty
  3. Optometry

A Multipronged Treatment Approach for a Multifaceted Disease: Formulating Personalized Management Plans for DED

A Multipronged Treatment Approach for a Multifaceted Disease Formulating Personalized Management Plans for DED
Media formats available:
Details
Presenters

  • Overview

    Approximately 16 million people of all ages in the United States have a formal dry eye disease (DED) diagnosis. However, DED is notoriously underdiagnosed.

    Join Drs. Garlich, Nichols, and Whitley for this educational symposium on DED. Learn from these experts about not only the signs and symptoms of DED but also the individual patient risk factors and comprehensive evaluations for these patients. The utility of point-of-care diagnostics, how artificial tears impact clinical outcomes, and the real-world value of the latest treatment options will also be discussed.

  • Commercial Support

    This activity is supported by unrestricted educational grants from Alcon, Sun Pharma, and Viatris.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Diagnose patients with dry eye disease (DED) using an algorithmic approach that considers the signs and symptoms as well as individual factors that increase the risk for disease
    • Relate the clinical manifestations of DED/meibomian gland dysfunction to the underlying pathophysiology
    • Perform comprehensive diagnostic evaluations for patients suspected to have DED, integrating point-of-care diagnostics where appropriate and beneficial
    • Explain how the composition and mechanism of action of artificial tears and DED treatments may influence clinical outcomes
    • Develop a personalized treatment plan that uses complementary treatment approaches, where appropriate, to improve the signs and symptoms of DED

  • Accreditation

    Evolve Medical Education, LLC is a COPE-accredited administrator.

    Sponsored by

    This activity, COPE Activity Number 129850, is accredited by COPE for continuing education for optometrists. This course is approved for 1.25 hours of CE.

    Course #: 95396-TD
    Activity #: 129850

    COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.

  • Faculty and Disclosures

    Kelly K. Nichols, OD, MPH, PhD, FAAO

    Kelly K. Nichols, OD, MPH, PhD, FAAO

    University of Alabama at Birmingham
    Professor and Dean of the
    School of Optometry
    Birmingham, AL

     

    Jaclyn Garlich, OD, FAAO

    Jaclyn Garlich, OD, FAAO

    Envision Optometry
    Boston, MA

     

    Walter O. Whitley, OD, MBA, FAAO

    Walter O. Whitley, OD, MBA, FAAO

    Director of Professional Relations and Education
    Virginia Eye Consultants
    Regional Medical Director
    Eyecare Partners, LLC
    Norfolk, VA

     

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Alcon, Alderya, Azura Ophthalmics, Bausch + Lomb, Bruder Healthcare, Cavalry, Dompé, HanAll Biopharma, Harrow, Novaliq, Novartis, Oyster Point Pharma, Sydnexis, Tarsus Pharmaceuticals, TearSolutions, Théa Pharma, Topcon, and Trukera Medical. Grant/Research Support: Aramis, Kowa, ScienceBased Health, Sylentis, and TearScience.

    Jaclyn Garlich, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Alcon, Aldeyra, Bausch + Lomb, Bruder Healthcare, Dompé, Lumenis, Novartis, Orasis Pharmaceuticals, Oyster Point Pharma, Tarsus Pharmaceuticals, and Théa Pharma. Speaker's Bureau: Bausch + Lomb and Tarsus Pharmaceuticals.

    Walter O. Whitley, OD, MBA, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Epion, Glaukos, Harrow, Iveric Bio, Mediprint Pharma, Regener-Eyes, Théa Pharma, Trukera, and Viatris. Speaker's Bureau: Alcon, Allergan, Apellis Pharmaceuticals, and Bausch + Lomb. Advisory Board: Alcon, Allergan, Bausch + Lomb, Bruder Healthcare, ScienceBased Health, Sun Pharma, Tarsus Pharmaceuticals, and Visus Pharmaceuticals. Medical Editor: Dry Eye Coach, Modern Optometry, and Review of Optometry.

    The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Sun Pharma, or Viatris.
    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free